Universidade De Santiago De Compostela
- Address
- lock Available on a paid plan
Neoplasms and Blood Cancer Research
At Universidade De Santiago De Compostela, clinical research is focused on neoplasms, with a strong emphasis on hematology and cancers affecting the blood and lymphatic system. The studies are centered on treatment-naïve mantle cell lymphoma, exploring new approaches to improve outcomes for people newly diagnosed with this rare cancer.
- Evaluating new treatment combinations for mantle cell lymphoma
- Assessing how effectively therapies can produce deep remission in hematologic malignancies
- Supporting better disease control for patients with newly diagnosed lymphoma
The research at this educational institution in Santiago De Compostela is aimed at testing whether modern treatment strategies can improve remission rates and strengthen care for patients with lymphoma.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 30 therapeutic areas and 15 of 763 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 730 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 145 by active trials.
- 1Novartis Pharma AG20active
lock +144 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG42trials
lock +83 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universidade De Santiago De Compostela
lock Showing 1 of 601 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 763 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 40 | Unknown | 2017-03-07 | 2026-07-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.